title: Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.
abstract: Paclitaxel is a cytotoxic agent with proven antitumour activity in metastatic breast cancer. Weekly administration of paclitaxel has demonstrated sustained efficacy together with a more favourable toxicity profile (e.g. less myelotoxicity) than the 3-weekly administration. This study evaluates the activity and toxicity of weekly paclitaxel (Taxol(R)) as first-line chemotherapy in elderly patients (>70 years of age) with hormone-refractory metastatic breast cancer. Patients with metastatic breast cancer received 80 mg/m(2) paclitaxel administered weekly on days 1, 8 and 15 of a 28-day cycle. Additional cycles were given until disease progression, or unacceptable toxicity. A dose increase to 90 mg/m(2) was allowed in the absence of toxicity. 26 Patients received a total of 101 cycles (median 4, range 1-11). 22 patients completed at least two cycles (six administrations). In 23 patients who were evaluable for response, there were 10 partial responses (38%), 9 patients with stable disease (35%), while 4 patients had disease progression (15%). The median duration of response was 194 days (>6 months). Overall treatment was relatively well tolerated, but 8 patients (32%) had to prematurely discontinue treatment because of fatigue. Neuropathy >grade 1 was noted only after five or more cycles in 4 patients. Weekly paclitaxel at this dose and schedule is an effective treatment regimen in the elderly patient with metastatic breast cancer, and is feasible, but yields relevant fatigue in a subset of patients.
authors.affiliation: Department of Medical Oncology, Erasmus MC (Rotterdam Cancer Institute)m Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands. a.tentije@erasmusmc.nl
authors.forename: A J
authors.initials: AJ
authors.lastname: ten Tije
authors.forename: C H
authors.initials: CH
authors.lastname: Smorenburg
authors.forename: C
authors.initials: C
authors.lastname: Seynaeve
authors.forename: A
authors.initials: A
authors.lastname: Sparreboom
authors.forename: K L C
authors.initials: KL
authors.lastname: Schothorst
authors.forename: L G M
authors.initials: LG
authors.lastname: Kerkhofs
authors.forename: L G P M
authors.initials: LG
authors.lastname: van Reisen
authors.forename: G
authors.initials: G
authors.lastname: Stoter
authors.forename: M
authors.initials: M
authors.lastname: Bontenbal
authors.forename: J
authors.initials: J
authors.lastname: Verweij
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D016019:Survival Analysis
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel